NEW YORK — OpGen last week filed an amended prospectus with US regulators to sell a mix of stock and warrants to raise up to $10.4 million to help fund its planned acquisition of German molecular diagnostics firm Curetis.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.